Samsungs investment plan boosts shares of biopharmaceutical firms

Published: 2010-05-14 06:58:00

Updated: 2010-05-14 06:58:00

Samsung Group’s announcement to spend 23.3 billion won on new businesses including biopharmaceuticals and medical devices on May 11 is a boon to local biomarkers as their shares skyrocketed recently.

Binex saw its shares gain the most on the junior Kosdaq market and shot up 14.9 percent to 12,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK